Company profile: InterVenn Biosciences
1.1 - Company Overview
Company description
- Provider of AI-driven glycoproteomic solutions, including the GlycoVision platform for biomarker discovery and disease insights; GlycoKnow Colon, a blood-based test for early colorectal cancer and adenoma detection; pharma services for discovery, validation, and drug development; clinical trial design support; and a knowledge graph integrating glycoproteomic and public data.
Products and services
- Pharma Services: Custom-engineered services that leverage glycoproteomic analysis to deliver biomarker discovery, validation, and drug development support for partner programs
- GlycoVision: An industrial-grade glycoproteomic platform that analyzes glycoproteins to discover biomarkers and generate insights into disease mechanisms for DX and Rx development
- GlycoKnow Colon: A clinical-grade, blood-based test utilizing glycoproteomic analysis for early detection of colorectal cancer and adenomas in patient samples
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to InterVenn Biosciences
Capintec
HQ: United States
Website
- Description: Provider of calibration and measurement technologies for nuclear medicine applications, offering advanced technology and services with a commitment to continuous quality improvement, including the Captus® 4000e Thyroid Uptake System for measuring thyroid uptake.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Capintec company profile →
Grey Wolf Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antigen modulation therapies that control T cell activation by modulating antigen presentation. Offers ERAP1 and ERAP2 inhibition to generate and upregulate cancer antigens, MHCI-directed therapies to identify novel antigens, and GRWD5769, a selective ERAP1 inhibitor in EMITT-1, an adaptive Phase 1/2 clinical trial assessing monotherapy and combinations with anticancer treatments in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grey Wolf Therapeutics company profile →
Avacta
HQ: United Kingdom
Website
- Description: Provider of technologies, consumables and reagents for life science markets from drug discovery to diagnostics; engaged in research, development, production and delivery of instrumentation and services for biopharmaceutical drug development and clinical diagnostics using biophysical technology. Offerings include the pre|CISION Platform, Affimer Technology, AVA6000, Launch Diagnostics (UK/France), and Coris Bioconcept rapid diagnostic test kits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avacta company profile →
Shorla Oncology
HQ: Ireland
Website
- Description: Provider of innovative oncology drugs focused on women's and pediatric cancers, developing and commercializing life-saving treatments that address unmet needs. Portfolio includes FDA-approved JYLAMVO (oral methotrexate) and TEPYLUTE for breast and ovarian cancer, as well as a Nelarabine Injection; pipeline programs include SH-201 under FDA review and SH-110 in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shorla Oncology company profile →
Terremoto Bio
HQ: United States
Website
- Description: Provider of a lysine-targeted covalency drug discovery and development platform to create optimized small-molecule medicines against a wide range of protein targets, including those previously considered undruggable. Offerings include structure-based drug design, screening platform development, cryo-EM, X-ray crystallography, and a computational discovery engine to accelerate new medicine creation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Terremoto Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for InterVenn Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to InterVenn Biosciences
2.2 - Growth funds investing in similar companies to InterVenn Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for InterVenn Biosciences
4.2 - Public trading comparable groups for InterVenn Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →